Pharmacology & Therapeutics

(The TQCC of Pharmacology & Therapeutics is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts. The publications cover those that have been published in the past four years, i.e., from 2019-03-01 to 2023-03-01.)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation2406
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function201
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy187
Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas182
Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases165
An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients152
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges150
The role of DNA methylation in epigenetics of aging144
The neuropsychopharmacology of cannabis: A review of human imaging studies144
Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders132
Recent therapeutic trends and promising targets in triple negative breast cancer124
Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies103
Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities99
ATM in DNA repair in cancer98
Senescence and senotherapeutics: a new field in cancer therapy97
TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward96
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer96
The role of flavonoids in autoimmune diseases: Therapeutic updates93
RNA therapy: Are we using the right molecules?88
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders87
Recent advances in the development of Mcl-1 inhibitors for cancer therapy85
Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer83
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies83
Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics83
Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease81
Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases81
Nanotechnology in the diagnosis and treatment of lung cancer80
PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression79
Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies77
CD26/DPP4 - a potential biomarker and target for cancer therapy75
DYRK1A and cognition: A lifelong relationship73
Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential73
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?71
Antifungal drugs: New insights in research & development71
Altered cancer metabolism in mechanisms of immunotherapy resistance70
An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy67
Heat shock proteins in fibrosis and wound healing: Good or evil?67
Acute kidney injury overview: From basic findings to new prevention and therapy strategies67
The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease66
Super-enhancers in cancer62
Statins: Adverse reactions, oxidative stress and metabolic interactions61
Mesenchymal stem cells: From regeneration to cancer60
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine59
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence59
Phosphodiesterases as therapeutic targets for respiratory diseases59
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity59
The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy57